Search results
Results from the WOW.Com Content Network
This occurs most commonly after the treatment of lymphomas and leukemias and in particular when treating non-Hodgkin lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia. [ 2 ] [ 3 ] This is a potentially fatal complication and people at an increased risk for TLS should be closely monitored while receiving chemotherapy and should ...
Pain and sensory abnormalities can persist for months or years after treatment completion. Some patients may experience “coasting,” where symptoms intensify after completion of treatment. [3] As such, patients can be cancer-free and still suffer from disabling neuropathy induced by cancer treatment. [3]
It is the most common mode of cell death in cancer cells exposed to ionizing radiation and many other anti-cancer treatments. [16] Immunogenic cell death or immunogenic apoptosis is a form of cell death caused by some cytostatic agents such as anthracyclines, oxaliplatin and bortezomib, or radiotherapy and photodynamic therapy (PDT). [17]
Research has revealed that neural progenitor cells are particularly vulnerable to the cytotoxic effects of chemotherapy agents. 5-fluorouracil has been demonstrated to reduce the viability of neural progenitor cells by 55–70% at concentrations of 1 μM, whereas cancer cell lines exposed to 1 μM of 5-fluorouracil were unaffected. [24]
In adaptation to higher tendency of cell death, blind mole rats evolved a mutation in the tumor suppressor protein p53 (which is also used in humans) to prevent cells from undergoing apoptosis. Human cancer patients have similar mutations, and blind mole rats were thought to be more susceptible to cancer because their cells cannot undergo ...
In patients with significant signs or symptoms, treatment can involve chemotherapy, immunotherapy, or chemoimmunotherapy. [4] The most appropriate treatment is based on the individual's age, physical condition, and whether they have the del(17p) or TP53 mutation. [14] As of 2024, the recommended first-line treatments include:
The National Cancer Institute estimated 22,070 new cases of primary brain cancer and 12,920 deaths due to the illness in the United States in 2009. The age-adjusted incidence rate is 6.4 per 100,000 per year, and the death rate is 4.3 per 100,000 per year. The lifetime risk of developing brain cancer for someone born today is 0.60%.
Comedocarcinoma is a kind of breast cancer that demonstrates comedonecrosis, which is the central necrosis [1] of cancer cells within involved ducts. Comedocarcinomas are usually non-infiltrating and intraductal tumors, characterized as a comedo-type, high-grade ductal carcinoma in situ (DCIS).